Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up

[1]  A. Luff,et al.  Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases , 2007, British Journal of Ophthalmology.

[2]  A. Schakal,et al.  Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. , 2007, Archives of ophthalmology.

[3]  M. Maia,et al.  Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES) , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  M. Larsen,et al.  Treatment of choroidal neovascularization using intravitreal bevacizumab. , 2007, Acta ophthalmologica Scandinavica.

[5]  W. Freeman,et al.  STANDARDIZED VISUAL ACUITY RESULTS ASSOCIATED WITH PRIMARY VERSUS SECONDARY BEVACIZUMAB (AVASTIN) TREATMENT FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION , 2007, Retina.

[6]  K. Bartz-Schmidt,et al.  Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[7]  David J. Wilson,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2007, Retina.

[8]  Arthur D. Fu,et al.  INTRAVITREAL BEVACIZUMAB FOR PREVIOUSLY TREATED CHOROIDAL NEOVASCULARIZATION FROM AGE-RELATED MACULAR DEGENERATION , 2007, Retina.

[9]  M. C. Donati,et al.  Intravitreal Bevacizumab Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: 6-Month Results of an Open-Label Uncontrolled Clinical Study , 2007, European journal of ophthalmology.

[10]  T. Wong,et al.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. , 2007, American journal of ophthalmology.

[11]  M. Farah,et al.  Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  N. Gabrić,et al.  Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[13]  R. Tibrewala,et al.  VISUAL IMPROVEMENT FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[14]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[15]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[16]  I. Scott,et al.  Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. , 2006, Investigative ophthalmology & visual science.

[17]  A. Bazarbachi,et al.  Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. , 2006, American journal of ophthalmology.

[18]  Sander R. Dubovy,et al.  SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[19]  Richard F Spaide,et al.  INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[20]  R. Avery,et al.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[21]  Philip J Rosenfeld,et al.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[22]  P. Rosenfeld,et al.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. , 2005, Ophthalmology.

[23]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[24]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[25]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[26]  T. Peto,et al.  The epidemiology of age-related macular degeneration. , 2004, American journal of ophthalmology.

[27]  Thomas J Liesegang,et al.  Safe and effective. , 2003, Ophthalmology.

[28]  Johanna M Seddon,et al.  Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. , 2003, Archives of ophthalmology.

[29]  G. Vrensen,et al.  Vascular endothelial growth factors and angiogenesis in eye disease , 2003, Progress in Retinal and Eye Research.

[30]  Joan W. Miller,et al.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. , 2002, Archives of ophthalmology.

[31]  Joan W. Miller,et al.  Mechanism of age related macular degeneration , 2002 .

[32]  I J Constable,et al.  Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. , 2000, The American journal of pathology.

[33]  P. Campochiaro,et al.  The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. , 1999, Molecular vision.

[34]  D. Eliott,et al.  Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. , 1996, American journal of ophthalmology.

[35]  S. Seregard,et al.  Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. , 1996, Investigative ophthalmology & visual science.

[36]  D. Hinton,et al.  Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. , 1996, Investigative ophthalmology & visual science.

[37]  F. Ferris,et al.  Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.

[38]  Neil M Bressler,et al.  Retinal arteriolar narrowing and risk of coronary heart disease. , 2003, Archives of ophthalmology.